7 research outputs found
Process of Manufacturing Nanoparticles (NGR Peptides with a Biodegradable Polymer) By Electrospraying for Developing an Active Targeting Drug Delivery System for Cancer Therapy
Cancer
â–ª 2nd leading cause of death in the U.S (Sudhakar, 2009)
Current Treatment Methods
â–ª Surgery, Chemotherapy, Radiation Therapy, Immunotherapy (Sudhakar, 2009)
Developing Methods
â–ª Cancer Nanotechnology (Passive and Active
1-s2.0-S0091679X23000870-main 2023.pdf
Myeloid-derived suppressor cells (MDSCs) are an integral part of the tumor microenvironment
(TME). MDSC’s involvement in the TME starts as soon as the primary tumor starts to get its
blood supply causing an immunosuppressive environment and tumor cell invasion, and then
at the formation of premetastatic niche through full-blown metastasis in distal organs. All of
these functions don’t require physical interaction of MDSC as some of the MDSC’s functions
can be replicated by secreted exosomes (MDSC-derived exosomes), which can alter the microenvironment
through cellular interaction by fusion with the plasma membrane and subsequent
release of their cargo, consisting of proteins, soluble factors, lipids, DNAs, microRNAs (miRNAs),
and RNAs. In this method paper, we explained how to isolate MDSC exosomes and how
to use the exosome to observe immunosuppressive function. We also discussed how to measure
the number of exosomes by nanoparticle tracking analysis. Additionally, we outlined how to
measure the protein of exosomes aswell as the types of protein by Bradford assay and membrane
cytokine array respectively. Wealso provided instructions on how to utilizeMDSC-derived exosomes
to get knowledge about in vitro immune cell migration, scratch assay with the tumor cells,
and in vivo effect of MDSC exosome along with T cell function and proliferation.</p
Isolation and immunosuppressive functions of myeloid-derived suppressor cell-derived exosomes
Myeloid-derived suppressor cells (MDSCs) are an integral part of the tumor microenvironment (TME). MDSC’s involvement in the TME starts as soon as the primary tumor starts to get supply causing an immunosuppressive environment and tumor cell invasion, and then at the formation of premetastatic niche through full-blown metastasis in distal organs. All of these functions don’t require physical interaction of MDSC as some of the MDSC’s functions can be replicated by secreted exosomes (MDSC-derived exosomes), which can alter the micro-environment through cellular interaction by fusion with the plasma membrane and subsequent release of their cargo, consisting of proteins, soluble factors, lipids, DNAs, microRNAs (miRNAs), and RNAs. In this method paper, we explained how to isolate MDSC exosomes and how to use the exosome to observe immunosuppressive function. We also discussed how to measure the number of exosomes by nanoparticle tracking analysis. Additionally, we outlined how to measure the protein of exosomes as well as the types of protein by Bradford assay and membrane cytokine array respectively. We also provided instructions on how to utilize MDSC-derived exosomes to get knowledge about in vitro immune cell migration, scratch assay with the tumor cells, and in vivo effect of MDSC exosome along with T cell function and proliferation.</p
Engineered exosomes for studies in tumor immunology
Exosomes are a type of extracellular vesicle (EV) with diameters of 30-150 nm secreted by most of the cells into the extracellular spaces and can alter the microenvironment through cell-to-cell interactions by fusion with the plasma membrane and subsequent endocytosis and release of the cargo. Because of their biocompatibility, low toxicity and immunogenicity, permeability (even through the blood-brain barrier (BBB)), stability in biological fluids, and ability to accumulate in the lesions with higher specificity, investigators have started making designer's exosomes or engineered exosomes to carry biologically active protein on the surface or inside the exosomes as well as using exosomes to carry drugs, micro RNA, and other products to the site of interest. In this review, we have discussed biogenesis, markers, and contents of various exosomes including exosomes of immune cells. We have also discussed the current methods of making engineered and designer's exosomes as well as the use of engineered exosomes targeting different immune cells in tumors, stroke, as well as at peripheral blood. Genetic engineering and customizing exosomes create an unlimited opportunity to use in diagnosis and treatment. Very little use has been discovered, and we are far away from reaching its limits.</p
Immunological Reviews - 2022 - Alptekin - Engineered exosomes for studies in tumor immunology-3.pdf
Exosomes are a type of extracellular vesicle (EV) with diameters of 30–150
nm secreted
by most of the cells into the extracellular spaces and can alter the microenvironment
through cell-to-
cell
interactions by fusion with the plasma membrane and
subsequent endocytosis and release of the cargo. Because of their biocompatibility,
low toxicity and immunogenicity, permeability (even through the blood–brain
barrier
(BBB)), stability in biological fluids, and ability to accumulate in the lesions with higher
specificity, investigators have started making designer's exosomes or engineered exosomes
to carry biologically active protein on the surface or inside the exosomes as
well as using exosomes to carry drugs, micro RNA, and other products to the site
of interest. In this review, we have discussed biogenesis, markers, and contents of
various exosomes including exosomes of immune cells. We have also discussed the
current methods of making engineered and designer's exosomes as well as the use
of engineered exosomes targeting different immune cells in the tumors, stroke, as
well as at peripheral blood. Genetic engineering and customizing exosomes create
an unlimited opportunity to use in diagnosis and treatment. Very little use has been
discovered, and we are far away to reach its limits.</p
17JBN-3091.pdf
Exosomes, a component of extracellular vesicles, are shown to carry important small RNAs, mRNAs, protein, and bioactive
lipid from parent cells and are found in most biological fluids. Investigators have demonstrated the importance of
mesenchymal stem cells derived exosomes in repairing stroke lesions. However, exosomes from endothelial progenitor
cells have not been tested in any stroke model, nor has there been an evaluation of whether these exosomes target/home
to areas of pathology. Targeted delivery of intravenous administered exosomes has been a great challenge, and a targeted
delivery system is lacking to deliver naïve (unmodified) exosomes from endothelial progenitor cells to the site of interest.
Pulsed focused ultrasound is being used for therapeutic and experimental purposes. There has not been any report
showing the use of low-intensity pulsed focused ultrasound to deliver exosomes to the site of interest in stroke models.
In this proof of principle study, we have shown different parameters of pulsed focused ultrasound to deliver exosomes
in the intact and stroke brain with or without intravenous administration of nanobubbles. The study results showed that
administration of nanobubbles is detrimental to the brain structures (micro bleeding and white matter destruction) at peak
negative pressure of >0.25 megapascal , despite enhanced delivery of intravenous administered exosomes. However,
without nanobubbles, pulsed focused ultrasound enhances the delivery of exosomes in the stroke area without altering
the brain structures.</p